Baird Reiterates Outperform on Instil Bio, Maintains $180 Price Target
Benzinga Newsdesk 2 years ago
NewsPrice TargetReiterationAnalyst Ratings
Baird analyst Jack Allen reiterates Instil Bio (NASDAQ:TIL) with a Outperform and maintains $180 price target.
Baird analyst Jack Allen reiterates Instil Bio (NASDAQ:TIL) with a Outperform and maintains $180 price target.